Page 2 - Regor Therapeutics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Regor therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Regor Therapeutics Today - Breaking & Trending Today

Pfizer accuses former employees of 'treachery' in stealing trade secrets to form Regor Therapeutics

Pfizer has accused two former employees who went on to form a new biotech of stealing “the hard work” of the Big Pharma’s own scientists for a diabetes and obesity program, according to a lawsuit filed Wednesday. ....

Min Zhong , New York , United States , Xiayang Qiu , Eli Lilly , National Institutes Of Health , Big Pharma , Regor Therapeutics , Defend Trade Secrets Act , National Institutes , Eli Lilly , Patent Lawsuit , Obesity Drugs , Diabetes Drugs ,

Regor Therapeutics Announces U.S. FDA Authorization to Conduct Regor's First-in-Human Clinical Trial with the Next Generation Targeted Inhibitor RGT-419B for Oncology

/PRNewswire/ On December 23, Regor Therapeutics, a clinical-stage biotech company, announced authorization from the US Food and Drug Administration (FDA) to. ....

Xiayang Qiu , Drug Administration , Regor Therapeutics ,

Regor Therapeutics Announces U.S. FDA Authorization to Conduct Regor's First-in-Human Clinical Trial with the Next Generation Targeted Inhibitor RGT-419B for Oncology

/PRNewswire/ On December 23, Regor Therapeutics, a clinical-stage biotech company, announced authorization from the US Food and Drug Administration (FDA) to. ....

Xiayang Qiu , Drug Administration , Regor Therapeutics ,

Regor Therapeutics Announces U.S. FDA Authorization to Conduct Regor's First-in-Human Clinical Trial with the Next Generation Targeted Inhibitor RGT-419B for Oncology

SHANGHAI, Dec. 28, 2021 /PRNewswire/ On December 23, Regor Therapeutics, a clinical-stage biotech company, announced authorization from the US Food and Drug Administration (FDA) to proceed with Regor's Phase 1 clinical development plans for RGT-419B. RGT-419B is a new generation CDK2/4/6, small molecule inhibitor with an optimized kinase activity spectrum. It is expected to improve the safety of. ....

Xiayang Qiu , Drug Administration , Regor Therapeutics ,

Week In Review: Shanghai Regor To Discover Metabolic Therapies For Lilly In $1.55 Billion Deal

FinancialContent fully hosted finance channel ....

Avistone Pharma , Eli Lilly , Regor Therapeutics , Beijing Avistone Pharma , Vivo Capital ,